Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Melanoma 1

Interventions

Magnetic Resonance Spectroscopy 281Specimen Handling 271pembrolizumab 253Cyclophosphamide 235Radiotherapy 227Nivolumab 184Cisplatin 172Biopsy 161Carboplatin 155Radiosurgery 143fludarabine 131Blood Specimen Collection 129Surveys and Questionnaires 120Gemcitabine 119Paclitaxel 116venetoclax 114Standard of Care 112Dexamethasone 107Bevacizumab 93Radiation 92Rituximab 91Oxaliplatin 89Cytarabine 88Ipilimumab 84Drug Therapy 84Capecitabine 84Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × famitinib × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡